Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.

[1]  C. Ohlmann.  Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.

[2]  K. Miller,et al.  Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. , 2009, European urology.

[3]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Sanders,et al.  Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. , 2008, The Journal of urology.

[5]  E. Basch,et al.  Targeted drugs for metastatic renal cell carcinoma , 2007, The Lancet.

[6]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[7]  S. Berndt,et al.  Disparities in treatment and outcome for renal cell cancer among older black and white patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Patard,et al.  Renal cell carcinoma guideline. , 2007, European urology.

[9]  J. Desai,et al.  Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.

[10]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Fosså,et al.  Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[15]  C. Stief,et al.  Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinoma , 2002, Cancer.

[16]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  K. Abe,et al.  Gender as a prognostic factor in patients with renal cell carcinoma , 2002, BJU international.

[18]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[19]  S. Barni,et al.  Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients , 2000, Urologia Internationalis.

[20]  R. Fisher,et al.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.

[21]  B. Escudier,et al.  Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. , 2000, The cancer journal from Scientific American.

[22]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Pyrhönen,et al.  Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. , 1999, Journal of immunotherapy.

[24]  R. Figlin.  Renal cell carcinoma: management of advanced disease. , 1999, The Journal of urology.

[25]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[26]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[27]  M. Burt,et al.  Resection of metastatic renal cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Bukowski.  Natural history and therapy of metastatic renal cell carcinoma , 1997, Cancer.

[29]  J. Blay,et al.  Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.

[30]  J. Chmiel,et al.  Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. , 1995, The Journal of urology.

[31]  J. Chmiel,et al.  Original Articles: Kidney Cancer: Renal Cell Carcinoma: Tumor Size, Stage and Survival , 1995 .

[32]  T. Philip,et al.  Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.

[34]  N. P. Patel,et al.  Renal cell carcinoma: natural history and results of treatment. , 1978, The Journal of urology.

[35]  D. Orrell.  Albumin as an aid to the interpretation of serum calcium. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[36]  S. Rafla,et al.  Renal cell carcinoma. Natural history and results of treatment , 1970, Cancer.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Jones,et al.  The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. , 1993, Cancer biotherapy.